Endocrine and Targeted Manipulation of Breast Cancer
Online CME Activity
This activity is published in the journal Cancer, Vol 112, Issue S3, pp 673-678, Feb 1, 2008: "Endocrine and Targeted Manipulation of Breast Cancer: Proceedings of the Sixth Cambridge Conference"
Up to 2 hours of AMA PRA Category 1 Credit™
Release date: December 2007 Valid through: December 2008
Course Material: CME Activity - PDF
Receiving CME Credit
To receive online CME credit for this activity, click below to complete the registration, test and evaluation.
You will have 2 opportunities to answer the questions correctly. Then you will be shown answers to any questions answered incorrectly, to be sure you understand the material. You will be able to print your CME certificate immediately following completion of the test and evaluation.
Target Audience
This activity is designed to meet the educational needs of medical oncologists and other medical professionals who assess and treat breast cancer patients.
Educational Objectives
Following completion of this activity, participants should be able to: understand the recent data from the major trials of endocrine therapy in early breast cancer and implications for patient care; understand the leading treatment strategies that combine endocrine therapy with chemotherapy and/or with biologic agents and implications for patient care; and discuss recent data on breast cancer prevention, and implications for patient care.
Educational Need
Our understanding of the roles of the estrogen receptor and other growth factor pathway interactions in breast cancer biology has accelerated over the past six years, fueled by advances in basic research, new studies of existing therapies, and clinical evaluation of several new agents. Oncologists who counsel and treat breast cancer patients need to be aware of the most current clinical trial data and recommendations for the use of these agents alone and in combination with other agents in early and late-stage disease and in breast cancer prevention.
Sponsorship and Accreditation
This enduring journal CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. (InforMEDical). InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.
Educational Grant Support
This program is supported by educational grants provided by: AstraZeneca Pharmaceuticals, Pfizer, Inc. and Novartis Pharmaceuticals.
Credit Designation
InforMEDical designates this continuing medical education activity for up to 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Financial Disclosure
Carlos L. Arteaga: Bristol-Myers Squibb: advisory board; Eli Lilly: grant support; Genentech: grant support; Merck: grant support; Monogram Biosciences: consultant; Sunesis: consultant. Angela M. Brodie: AstraZeneca: advisory board, research support; Novartis: research support; Pfizer: advisory board. Aman U. Buzdar: AstraZeneca: research funding; Bristol-Myers Squibb: research funding; Eli Lilly: research funding; Genentech: research funding; Pfizer: research funding; Taiho: research funding. Steven E. Come: AstraZeneca: consulting, research support, Speakers’ Bureau; Novartis: Speakers’ Bureau; Pfizer: Speakers’ Bureau. Charles Coombes: AstraZeneca: research support; Pfizer: honoraria, research support. Paul E. Goss: AstraZeneca: advisory board, Speakers’ Bureau; GlaxoSmithKline: advisory board, Speakers’ Bureau; Pfizer: advisory board, Speakers’ Bureau; Novartis: advisory board, Speakers’ Bureau. James N. Ingle: Novartis: consultant. Stephen RD Johnston: AstraZeneca: research funding; GlaxoSmithKline: research funding, Speakers’ Bureau. William R. Miller: AstraZeneca: honoraria, Speakers’ Bureau; Novartis: honoraria, Speakers’ Bureau; Pfizer: honoraria, Speakers’ Bureau. Kathleen L. Pritchard: Aefera: advisory committee, honoraria; Amgen: research funding; AstraZeneca: advisory committee, consultant, expert testimony, honoraria, research funding. Biomira: consultant.Bristol-Myers Squibb: research funding. Hoffmann-La Roche: advisory committee, consultant, honoraria; National Cancer Institute of Canada: research funding; Novartis: advisory committee, consultant, honoraria, research funding. Ortho-Biotech: advisory committee, consultant, research funding. Pfizer: advisory committee, consultant, honoraria, research funding; sanofi-aventis: advisory committee, consultant, expert testimony, honoraria, research funding; YM Biosciences: advisory committee, consultant, honoraria, research funding. Eric P. Winer: AstraZeneca: advisory board; Pfizer: advisory board. Jo Ann Zujewski: Nothing to disclose.